SOBI (SOBI) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
30 Jun, 2026Executive summary
Achieved full-year 2024 revenue growth of 19% to SEK 26,027M, with Q4 revenue up 8% year-over-year at constant exchange rates.
Adjusted EBITDA/EBITA margin was 36% for the year and 34% in Q4, reflecting strong portfolio performance and ongoing investments.
Strategic growth portfolio expanded rapidly, now representing up to 55% of Q4 revenues, driven by launches and new indications.
Significant pipeline progress with multiple regulatory filings and launches, including Altuvoct, Aspaveli, and Gamifant.
Board proposes no dividend for 2024; David Meek elected as new Chair.
Financial highlights
Q4 revenues reached SEK 7,436M, surpassing SEK 7 billion in a single quarter for the first time.
Profit for the period was SEK 3,879M for FY 2024, up 36% year-over-year; Q4 profit SEK 1,391M, up 36%.
Adjusted EPS before dilution for FY 2024 was SEK 11.83, up 26%; Q4 adjusted EPS SEK 4.03, up 26%.
Operating cash flow for FY 2024 was SEK 7,388M, up 67% year-over-year.
Net debt reduced to SEK 15,194M from SEK 19,265M at the end of 2023; net debt/EBITDA at 1.6x.
Outlook and guidance
2025 revenue expected to grow at a high single-digit percentage at constant exchange rates.
Adjusted EBITDA/EBITA margin for 2025 guided to mid-30s, reflecting continued investment in launches and R&D.
Margin expansion anticipated beyond 2025 as scale increases and launch-related expenses moderate.
Latest events from SOBI
- Strategic portfolio growth and robust margins drive strong Q1 2025 results and outlook.SOBI
Q1 20258 Jul 2026 - Strong 2025 revenue and margin growth driven by strategic launches and pipeline progress.SOBI
Q4 20258 Jul 2026 - Q3 2025 saw 21% CER revenue growth, 47% margin, and upgraded 2025 guidance.SOBI
Q3 20258 Jul 2026 - Q1 2026 revenue up 24% at CER, 38% margin, pipeline boosted by Arthrosi acquisition.SOBI
Q1 202628 Apr 2026 - Doubling revenue to SEK 55bn by 2030, driven by major launches and global expansion.SOBI
Investor presentation13 Mar 2026 - Doubling revenue to SEK 55bn by 2030, driven by six major launches and global expansion.SOBI
CMD 202618 Feb 2026 - Acquisition of a late-stage gout therapy for $950M upfront drives growth into the 2040s.SOBI
M&A Announcement3 Feb 2026 - Pegcetacoplan achieved a 68% proteinuria reduction with strong safety in phase 3 C3G/IC-MPGN trial.SOBI
Study Result3 Feb 2026 - Q2 revenue up 11% with 74% CER portfolio growth and margin gains, supporting upgraded guidance.SOBI
Q2 20243 Feb 2026